CN103908604B - For preparation treating osteoarthritis and preparation method thereof - Google Patents
For preparation treating osteoarthritis and preparation method thereof Download PDFInfo
- Publication number
- CN103908604B CN103908604B CN201410180088.XA CN201410180088A CN103908604B CN 103908604 B CN103908604 B CN 103908604B CN 201410180088 A CN201410180088 A CN 201410180088A CN 103908604 B CN103908604 B CN 103908604B
- Authority
- CN
- China
- Prior art keywords
- parts
- preparation
- weight
- powder
- saualane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000843 powder Substances 0.000 claims description 20
- 201000008482 osteoarthritis Diseases 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 241000219784 Sophora Species 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 11
- 241000209205 Coix Species 0.000 claims description 10
- 235000007354 Coix lacryma jobi Nutrition 0.000 claims description 10
- 241000521581 Millettia Species 0.000 claims description 10
- 244000242564 Osmanthus fragrans Species 0.000 claims description 10
- 235000019083 Osmanthus fragrans Nutrition 0.000 claims description 10
- 235000009499 Vanilla fragrans Nutrition 0.000 claims description 10
- 235000012036 Vanilla tahitensis Nutrition 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 10
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims description 9
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 9
- 229960002442 glucosamine Drugs 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 235000015398 thunder god vine Nutrition 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 241000196324 Embryophyta Species 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 235000011837 pasties Nutrition 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 244000263375 Vanilla tahitensis Species 0.000 claims 3
- 230000000694 effects Effects 0.000 description 15
- 208000002193 Pain Diseases 0.000 description 14
- 210000000988 bone and bone Anatomy 0.000 description 8
- 244000290333 Vanilla fragrans Species 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 208000006820 Arthralgia Diseases 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- 210000000845 cartilage Anatomy 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 210000001503 joint Anatomy 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- 208000012659 Joint disease Diseases 0.000 description 3
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000008407 joint function Effects 0.000 description 3
- 210000000629 knee joint Anatomy 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 208000036487 Arthropathies Diseases 0.000 description 2
- 241000345998 Calamus manan Species 0.000 description 2
- 241000251730 Chondrichthyes Species 0.000 description 2
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000004417 patella Anatomy 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 235000012950 rattan cane Nutrition 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000014101 wine Nutrition 0.000 description 2
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241001260012 Bursa Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Natural products CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 1
- 241000236488 Lepra Species 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 235000019082 Osmanthus Nutrition 0.000 description 1
- 241000333181 Osmanthus Species 0.000 description 1
- 206010057178 Osteoarthropathies Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010037714 Quadriplegia Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 108010055297 Sterol Esterase Proteins 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- OUCXYSRPMBQONT-UHFFFAOYSA-N acetamide;phenol Chemical compound CC(N)=O.OC1=CC=CC=C1 OUCXYSRPMBQONT-UHFFFAOYSA-N 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000010692 aromatic oil Substances 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000001255 hallux Anatomy 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000005110 hydrotaxis Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 244000000053 intestinal parasite Species 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 201000005630 leukorrhea Diseases 0.000 description 1
- 229960002373 loxoprofen Drugs 0.000 description 1
- YMBXTVYHTMGZDW-UHFFFAOYSA-N loxoprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1CC1C(=O)CCC1 YMBXTVYHTMGZDW-UHFFFAOYSA-N 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000003349 osteoarthritic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- SBNFWQZLDJGRLK-UHFFFAOYSA-N phenothrin Chemical compound CC1(C)C(C=C(C)C)C1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 SBNFWQZLDJGRLK-UHFFFAOYSA-N 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960000953 salsalate Drugs 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 239000003190 viscoelastic substance Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
This, for treating the preparation of osteoarthritis, is made up of reticulate millettia, thunder godvine, the sophora bud, sweet osmanthus, elm money, cortex acanthopanacis, vanilla, Job's tears, saualane, Glucosamine.Preparation this for the method for the treatment of osteoarthritis preparation, comprise the following steps: a, by reticulate millettia, thunder godvine respectively by 95% ethanol heating and refluxing extraction twice, each 2 hours, merge extract, concentration is evaporated, powder process；B, the sophora bud, sweet osmanthus, elm money are respectively prepared the powder of 300～350 mesh；C, join cortex acanthopanacis, vanilla in 100 parts of water to decoct and take its filtrate half an hour；Job's tears is added in described filtrate, is heated to pasty state, dry powder process；D, by the powder in step a, step b, step c；Join in saualane, Glucosamine, stir；It is fabricated to plant capsule according to 0.68 gram one.
Description
Technical field
The invention belongs to field of medicaments, a kind of for preparation treating osteoarthritis and preparation method thereof.
Background technology
Osteoarthritis (osteoarthritis, OA) is that one is with Articular cartilage degeneration and Secondary cases osteoproliferation
The chronic joint diseases of characteristic.Being more common in the elderly, women is more than the male sex.Be apt to occur in the bigger knee joint of bearing a heavy burden, hip joint,
The positions such as lumbosacral region joint of vertebral column (Lumbosacral joint) and the first toe joint (First MIP joints), and
The DIPJ (DIP joints) of hand, PIP (PIP joints).This disease is also known as osteoarthropathy, moves back
Row arthritis, hyperplasia row arthritis, degenerative arthritis etc..Along with the aging and fat ratio of population rises, Bones and joints
Scorching prevalence rate will improve.
General treatement: often have a rest, want Saving cortilage, it is to avoid acutely, excessively and the activity born a heavy burden (is squatted down, bends over, climbed
Stair, go on a journey, carry weight, climb the mountain), during major injury, support to be lain up is fixing prevents deformity.It addition, strengthen joint week
The muscle strength on limit, reduces joint wear；And disperse joint to bear a heavy burden through crutch, knee-pad.Cross severe one and must control body weight,
Reduce joint burden.
Medicinal treatment: acetyl ammonia phenol: be process pain First Line medication, only analgesic effect and without anti-inflammatory effect,
But side effect is slighter.It is administered orally or external application non-steroidal anti-inflammatory anodyne (NSAID): the most commonly used, including: Naproxen,
Salsalate, Ibuprofen, Diclofenac, can alleviate pain and reduce inflammation；There are about the patient of 30% to take on-steroidal and disappear
Scorching anodyne can produce UGI malaise symptoms, including indigestion, abdominal distension, feel sick, hemorrhage of digestive tract, ulcer；It addition,
Fraction patient NSAID likely can cause oedema or affect renal function.Clinical study results shows, external application NSAID
Effect is slightly worse but various few side effects much, but still have and stimulate the possibility of skin.Intra articular injection sodium hyaluronate
(Hyaluronate), this is that the rheological behavior by it is supplemented as visco-elastic material, and effect is that lubricating joint Saving cortilage is soft
Bone.Intra articular injection steroids: bursa synovialis inflammation is the main cause of osteo-arthritic pain, therefore local injection anti-inflammatory drug is permissible
Effective pain relieving.But in clinical testing, although the analgesic effect of steroids is pretty good but effect duration is only than placebo
Many about 2 weeks, it is used in short-term pain relieving the most at most.
Summary of the invention
It is an object of the invention to provide a kind of for preparation treating osteoarthritis and preparation method thereof.
The preparation for treating osteoarthritis of the present invention, by the bulk drug of following parts by weight: reticulate millettia 4～6 parts, thunder
Public rattan 5～9 parts, the sophora bud 3～5 parts, sweet osmanthus 4～6 parts, elm money 8～12 parts, cortex acanthopanacis 7～10 parts, vanilla 4～6 parts, Job's tears 7～
9 parts, saualane 8～12 parts, Glucosamine 6～10 parts are made.
As optimization, this is for treating the preparation of osteoarthritis, by the bulk drug of following parts by weight: reticulate millettia 5 parts, thunder
Public 6 parts of rattan, the sophora bud 3.5 parts, sweet osmanthus 4 parts, elm money 9 parts, cortex acanthopanacis 7 parts, vanilla 4.5 parts, Job's tears 8 parts, saualane 10 parts, amino
Glucose 9.5 parts is made.
Preparation originally for the method treating osteoarthritis preparation, comprises the following steps:
A, by the reticulate millettia of described parts by weight, thunder godvine respectively by 95% ethanol heating and refluxing extraction twice, each 2 little
Time, merging extract, concentration is evaporated, powder process；
B, the sophora bud by described parts by weight, sweet osmanthus, elm money are respectively prepared the powder of 300～350 mesh；
C, join the cortex acanthopanacis of described parts by weight, vanilla in 100 parts of water to decoct and take its filtrate half an hour；By described
The Job's tears of parts by weight adds in described filtrate, is heated to pasty state, dries powder process；
D, by the powder in step a, step b, step c；Join the saualane of described parts by weight, Glucosamine
In, stir；It is fabricated to plant capsule according to 0.68 gram one.
The present invention is in the preparation recipe treating osteoarthritis, and thunder godvine effect is dispelled rheumatism, removes obstruction in channels to relieve pain, only subsided a swelling
Bitterly, removing toxic substances desinsection.For damp and hot tubercle, the long-pending poison of carcinoma, treat lepra reaction, rheumatoid arthritis etc. with it clinically, have
Antitumor, anti-inflammatories etc. act on.
The sophora bud has cold, and taste is sweet flat；Enter liver, large intestine channel.
Sophora bud cooling blood and hemostasis, clearing liver fall fire.Curing mainly hematochezia, hemorrhoid blood, hematuria, blood drenches, uterine bleeding, dysentery, hot eyes, sore
Poison, the illness such as hypertension.
Job's tears taste is sweet, light, cold nature.There are invigorating spleen to remove dampness, clearing away heat and eliminating pus function.For splenasthenic diarrhea oedema tinea pedis, leukorrhea,
The diseases such as wet, arthralgia, acute appendicitis, consumptive lung disease.
Sweet osmanthus effect: yellowish white, fragrance, extract aromatic oil, osmanthus concrete processed, can be used for food, cosmetics, can cake processed
Select, candy, and can make wine.Function cures mainly: flower: dissipate cold broken knot, preventing phlegm from forming and stopping coughing.For having a toothache, cough that to breathe heavily phlegm many, through closing stomachache.
Elm hydrotaxis is put down, and taste is sweet, micro-pungent；Enter lung, spleen, the heart channel of Hang-Shaoyin.Having spleen-benefiting mind-tranquilizing, clearing heart fire, relieving cough and reducing sputum, heat-clearing is sharp
Water, effect of desinsection detumescence.Curing mainly insomnia, poor appetite, under band, difficult urination, oedema, children's's infantile malnutrition due to digestive disturbances or intestinalparasites heat is thin thin, burn and scald, sore
The illnesss such as tinea.
Cortex acanthopanacis has the effects such as wines used as antirheumatic, filling liver kidney, strengthening the bones and muscles.It is viscous that product also have antitumor, antifatigue, reduction whole blood
Degree, atherosclerosis formation etc. act on.
Reticulate millettia look red enter blood, matter profit row dissipate；Have and activate blood and relax tendons, effect of nourishing blood for regulating menstruation；Cure mainly arthralgia due to wind-dampness, brothers
Numbness, quadriplegia, irregular menstruation, blockage of menstruation, dysmenorrhoea, through closing, leukopenia.
Vanilla herb can be used as medicine, the big temperature of property, enters liver kidney channel, temperature kidney yang, moistening lung enriching yin, and dispel Wen Han, has kidney tonifying wind dispelling, supporing yang
Analgesic effect, have refreshing people's body and mind, quiet brain to calm the nerves, lax nerve, relieving fatigue, remove obstruction in channels to relieve pain, the effect of kidney tonifying nourishing and strengthening vital.
Saualane be the large-scale shark in abyssal environment liver in pinch go out highly finished product, by six isoprene double bond groups
The hydrocarbons become, belongs to polyisoprenoid structure.Squalene does not only exists in shark liver, and is the internal substance in human body.
Participate in courage in vivo because of the biosynthesis of alcohol and multiple biochemical reaction, promote biological oxidation and the metabolism of body, improve machine
The defensive enginery of body, stress ability and body and mind quality, acceleration class, because of alcohol hormone sensitive lipase gene, the activity of activated adenyl cyclase, is drawn
The Level of Camp playing second messenger increases.
The releive pain because arthritis causes, stiff and swelling osteoporosis of Glucosamine makes cartilage consume, finally
Causing fragmentation to be peeled off, the buffering of cartilage has been lacked in joint, is easily generated the stiff and inflammation of misery.And gucosamine contributes to reparation and is subject to
Damage cartilage, stimulate the generation of new cartilage, improve inflammation symptom, arthralgia of releiving, stiff and swelling.
Various active components compatibility of the present invention, bone is good in promoting blood circulation and removing obstruction in channels, tonifying Qi, it is possible to is effectively improved arthralgia and promotes bone
Joint function recovery, promotes bone cell proliferation, differentiation；Treatment osteoarthritis effect is notable.Relevant clinical data is as follows.
Physical data: 800 example knee osteoarthritis patients, unilateral 530 examples, bilateral 270 example.The maleest 290 examples, female 510
Example；Age 41～66 years old, average 53.33 years old.The course of disease 5 months～6 years., it is randomly divided into treatment group 400 example and control group 400 example.
Diagnostic criteria: meet the OA diagnostic criteria that Americanism diseases caused by dampness association determines；Knee joint osteoarthritis criteria for classification is such as
Under: kneecap arthropathy diagnose: (1) front moon most of time have goinyalgia, (2) have joint crepitus, (3) deadlock in morning time < 30min,
(4) age > 38 years old, (5) have bone to expand.Meet 1+2+3+4 bar or 1+2+5 bar or 1+4+5 bar person can make kneecap arthropathy
Diagnosis.Knee osteoarthritis diagnose: (1) front moon most of time have goinyalgia, (2) spur formed, (3) joint fluid inspection meet bone close
Joint inflammation, (4) age, < 40 years old, (5) deadlock in morning time, < 30min, (6) had bony crepitus.Meet 1+2 bar or 1+3+5+6 bar or 1+,4+5 ten
Bar person can make knee osteoarthritis diagnosis.
Methods for the treatment of: control group simple oral drug therapy: loxoprofen sodium dispersible tablets, 1 tablet/time, three times on the one；Hydrochloric acid
Glucosamine capsule: 11 time, twice on the one, 35 days courses for the treatment of.The treatment group use embodiment of the present invention 1 Chinese traditional medicine, 3 times on the 1st,
1 time 2,35 days courses for the treatment of.
Efficacy evaluation: arthralgia: effective: detumescence, without arthralgia；Effective: pain is light, still can stand or only tired
Or pain during Changes in weather, have substantially no effect on work；Invalid: pain is heavier, working and having a rest all is affected, need to be with the use of
Analgesic drug product.Articular pain: effective: joint is without tenderness；Effective: tenderness is lighter；Invalid: tenderness is obvious, pain can not be touched, it is difficult to bears
It is subject to.The results are shown in Table 1.Using HSs scale to evaluate patient bone joint function recovery situation, these scale full marks are 100, wherein
Pain 30 points, function 22 points, mobility 18 points, muscular strength 10 points, deformity 10 points, stability 10 points, score is the highest shows knee joint
Function is the best.The results are shown in Table 2.
Result:
Detailed description of the invention
The invention will be further described for example given below plan, but is not to be construed as scope
Restriction, those skilled in the art, according to some nonessential improvement and adjustment to the present invention of present invention, still fall within this
The protection domain of invention.
Embodiment 1, a, takes reticulate millettia 5 grams, thunder godvine 6 grams respectively by 95% ethanol heating and refluxing extraction twice, each 2 little
Time, merging extract, concentration is evaporated, powder process；B, take the sophora bud 3.5 grams, sweet osmanthus 4 grams, elm money 9 grams are respectively prepared 300～350 purposes
Powder；C, take cortex acanthopanacis 7 grams, vanilla 4.5 grams joins to decoct after half an hour in 100 grams of water and takes its filtrate；Take Job's tears 8 grams addition
In described filtrate, it is heated to pasty state, dries powder process；D, by the powder in step a, step b, step c；Connection saualane 10 grams,
Glucosamine 9.5 grams joins in mixer and stirs, then according to 0.68 gram one is fabricated to plant capsule.
Embodiment 2, a, takes reticulate millettia 4 grams, thunder godvine 5 grams respectively by 95% ethanol heating and refluxing extraction twice, each 2 little
Time, merging extract, concentration is evaporated, powder process；B, take the sophora bud 3 grams, sweet osmanthus 4 grams, elm money 8 grams are respectively prepared the powder of 300～350 mesh
End；C, take cortex acanthopanacis 7 grams, vanilla 4 grams joins to decoct after half an hour in 100 grams of water and takes its filtrate；Take Job's tears 7 grams and add described
In filtrate, it is heated to pasty state, dries powder process；D, by the powder in step a, step b, step c；Connection saualane 8 grams, amino Portugal
Grape sugar 6 grams joins in mixer and stirs, then according to 0.68 gram one is fabricated to plant capsule.
Embodiment 3, a, takes reticulate millettia 6 grams, thunder godvine 9 grams respectively by 95% ethanol heating and refluxing extraction twice, each 2 little
Time, merging extract, concentration is evaporated, powder process；B, take the sophora bud 5 grams, sweet osmanthus 6 grams, elm money 12 grams are respectively prepared 300～350 purposes
Powder；C, take cortex acanthopanacis 10 grams, vanilla 6 grams joins to decoct after half an hour in 100 grams of water and takes its filtrate；Take Job's tears 9 grams addition
In described filtrate, it is heated to pasty state, dries powder process；D, by the powder in step a, step b, step c；Connection saualane 12 grams,
Glucosamine 10 grams joins in mixer and stirs, then according to 0.68 gram one is fabricated to plant capsule.
Claims (2)
1. one kind for treating the preparation of osteoarthritis, it is characterised in that is by the bulk drug of following parts by weight: reticulate millettia 4～
6 parts, thunder godvine 5～9 parts, the sophora bud 3～5 parts, sweet osmanthus 4～6 parts, elm money 8～12 parts, cortex acanthopanacis 7～10 parts, vanilla 4～6 parts,
Job's tears 7～9 parts, saualane 8～12 parts, Glucosamine 6～10 parts, made by following steps；
A, by the reticulate millettia of described parts by weight, thunder godvine respectively by 95% ethanol heating and refluxing extraction twice, each 2 hours, close
And extract, concentration is evaporated, powder process；
B, the sophora bud by described parts by weight, sweet osmanthus, elm money are respectively prepared the powder of 300～350 mesh；
C, join the cortex acanthopanacis of described parts by weight, vanilla in 100 parts of water to decoct and take its filtrate half an hour；By described weight
The Job's tears of number adds in described filtrate, is heated to pasty state, dries powder process；
D, the powder in step a, step b, step c is joined in the saualane of described parts by weight, Glucosamine, stirring
Uniformly；It is fabricated to plant capsule according to 0.68 gram one.
Preparation for treating osteoarthritis the most according to claim 1, it is characterised in that by following parts by weight
Bulk drug is made: reticulate millettia 5 parts, thunder godvine 6 parts, the sophora bud 3.5 parts, sweet osmanthus 4 parts, elm money 9 parts, cortex acanthopanacis 7 parts, vanilla 4.5 parts,
Job's tears 8 parts, saualane 10 parts, Glucosamine 9.5 parts.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410180088.XA CN103908604B (en) | 2014-04-30 | 2014-04-30 | For preparation treating osteoarthritis and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410180088.XA CN103908604B (en) | 2014-04-30 | 2014-04-30 | For preparation treating osteoarthritis and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103908604A CN103908604A (en) | 2014-07-09 |
| CN103908604B true CN103908604B (en) | 2016-08-24 |
Family
ID=51034808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410180088.XA Expired - Fee Related CN103908604B (en) | 2014-04-30 | 2014-04-30 | For preparation treating osteoarthritis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103908604B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1342462A (en) * | 2000-09-08 | 2002-04-03 | 何兴峰 | Composite medicine for treating rheumatoid arthritis |
| CN103191212A (en) * | 2013-03-26 | 2013-07-10 | 鲁道宗 | Externally used traditional Chinese medicine powder for treating osteoarthritis and preparation method thereof |
-
2014
- 2014-04-30 CN CN201410180088.XA patent/CN103908604B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1342462A (en) * | 2000-09-08 | 2002-04-03 | 何兴峰 | Composite medicine for treating rheumatoid arthritis |
| CN103191212A (en) * | 2013-03-26 | 2013-07-10 | 鲁道宗 | Externally used traditional Chinese medicine powder for treating osteoarthritis and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 内服中药治疗骨关节炎用药概况;李荣亨等;《全国中西医结合强直性脊柱炎专题研讨会论文汇编》;20071231;第331-335页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103908604A (en) | 2014-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101062194B (en) | Medicine for treating bone disease and fracture and the preparing method thereof | |
| CN102284000B (en) | Medicated liquor | |
| CN103705758A (en) | Traditional Chinese medicament for treating cervical spondylosis | |
| CN102078586A (en) | Medicament for treating cervical spondylosis | |
| CN103100003B (en) | Traditional Chinese medicine composition for treating acute gouty arthritis | |
| CN103908604B (en) | For preparation treating osteoarthritis and preparation method thereof | |
| CN100540045C (en) | A kind of Chinese medicine for the treatment of lumbago and skelalgia | |
| CN103599321B (en) | Traditional Chinese medicine composition for treating osteoporosis | |
| CN103301401B (en) | A kind of medicated wine and preparation method thereof | |
| CN106729440A (en) | A kind of Chinese drugs agentia for treating insomnia | |
| CN106362066A (en) | Medicinal liquor for treatment of rheumatic and rheumatoid diseases and preparation method thereof | |
| Khan et al. | Understanding the concept of Purgation (Ishal) in Unani Medicine: A Review. | |
| CN106138960B (en) | Medical composition and its use | |
| CN108904705A (en) | A kind of Chinese medicine composition for treating postmenopausal women gouty arthritis,chronic | |
| CN103768538B (en) | A kind of medicine for the treatment of knee osteoarthritis | |
| CN103989968A (en) | Oral traditional Chinese medicinal composition for treating cervical spinal stenosis | |
| CN117338889B (en) | Essential oil composition for preventing and treating blood stasis syndrome and application thereof | |
| CN106822271A (en) | It is a kind of to treat pharmaceutical composition of rheumatic Bi syndrome and its production and use | |
| KR20240087884A (en) | Health functional asthma improvement and treatment composition | |
| CN104689176B (en) | A kind of Chinese medicine preparation for treating knee osteoarthritis and preparation method thereof | |
| Fazil et al. | QAI (EMESIS): FROM ANCIENT TO MODERN ERA AND ITS THERAPEUTIC EFFICACY IN VARIOUS DISORDERS | |
| CN103251851B (en) | Internal and external traditional Chinese medicine formulation for treating rheumatic and rheumatoid diseases | |
| CN112826911A (en) | Medicine for quickly treating cold-dampness type rheumatoid arthritis | |
| CN106309926A (en) | Composition prepared from bee products and medical and edible dual-purpose food and used for treating gastritis and gastric ulcer | |
| CN104189757A (en) | Traditional Chinese medicine for treating alcoholic liver |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: LI BAOJI Free format text: FORMER OWNER: ZHAI FENG Effective date: 20150416 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Li Baoji Inventor before: Di Feng |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: ZHAI FENG TO: LI BAOJI Free format text: CORRECT: ADDRESS; FROM: 043400 LINFEN, SHAANXI PROVINCE TO: 030024 TAIYUAN, SHAANXI PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20150416 Address after: 030024 No. 19 West Main Street, Wan Berlin District, Shanxi, Taiyuan, Yingze Applicant after: Li Baoji Address before: 043400 Shanxi city of Linfen province Quwo County Street Applicant before: Di Feng |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| CB03 | Change of inventor or designer information |
Inventor after: Xiu Xiaoguang Inventor after: Hou Rongyao Inventor after: Sun Yan Inventor before: Li Baoji |
|
| COR | Change of bibliographic data | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20160627 Address after: Shibei District People's road 266033 Shandong city of Qingdao province No. 4 Applicant after: Qingdao Hiser Medical Center Address before: 030024 No. 19 West Main Street, Wan Berlin District, Shanxi, Taiyuan, Yingze Applicant before: Li Baoji |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160824 Termination date: 20170430 |